#hpbcsm hasil pencarian
Aptly named BEER🍻 BTC #Ph2 trial in @JCO_ASCO In advanced #hpbcsm switching maintenance between 🍺bevacizumab ↔️ 🥃erlotinib after 6 months of gemcitabine-based therapy ⬆️ #PFS over active surveillance. #GIonc @OncoAlert🚨 ascopubs.org/doi/10.1200/JC…
Lenvatinib in combination with blank-microsphere transarterial chemembolization and sequential microwave ablation demonstrates encouraging preliminary activity in patients with hepatocellular carcinoma. #hpbcsm #GI23 | @ASCO ow.ly/OYu250MwZNF
📰Extra! Extra!📰 @OncoAlert Newsletter is live #GIonc studies include: 🌟 Pemigatinib 🎯in Advanced #Cholangiocarcinoma #hpbcsm 🌟#HIMALAYA 🏔️ tremelimumab+ durvalumab in #HCC Never miss an edition by signing up here: OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……
The OncoAlert🚨Newsletter, EVERY WEEK! This week Covering April 11-17, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅TALAPRO2 in #ProstateCancer ✅SBRT☢️ & IO in #KidneyCancer ✅ Challenges in #SCLC heterogeneity &Plasticity🫁
#GIonc in @JAMAOnc #ACCORD trial: Adjuvant camrelizumab + chemoradiation vs observation in resected EHC/GBC (n=93) #hpbcsm ⬆️ #OS (3y 58% vs 31%) + #RFS (3y 40% vs 17%) ⬇️ #tox Synergistic over chemo alone 💉☢️ 🔗: jamanetwork.com/journals/jamao… @doctorC369 @RyanNipp @supriyadocc
The #OncoAlertTopTweet 🚨 Day1⃣of #ASCO23 🇺🇸 Tweet by our OncoAlert faculty @pashtoonkasi IMBRAVE050 Adjuvant Atezo➕BEV For hepatocellular cancer (HCC) #HPBCSM. 78% 🆚 65% 12 month RFS rate. Best @weoncologists
IMBRAVE050 Adjuvant Atezo➕BEV For hepatocellular cancer (HCC) #HPBCSM. @OncoAlert #ASCO23 78% 🆚 65% 12 month RFS rate. What do folks think? Good enough as an endpoint or wait till OS data?
Opting for a less effective LC modality can be strategic to ensure success in the experimental arm. Plus, PFS is a cheeky endpoint in #EMERALD1. Considering bevacizumab's potential to obscure progression, we need different endpoints, such as OS. #TACE #hpbcsm
The vast majority (if not all) deal with local control. Nobody denies radiation is a great local control tool. But what matters is survival, or post-LT outcomes. Meanwhile the oncological community talks about combining TACE+immunotherapy (e.g. EMERALD-1 trial). Hold you nails.
⚡️#GIonc Update⚡️IMbrave150 🦾 Atezo + bev in #HCC #hpbcsm 77.8% partial response (PR) + 41 stable disease (SD) PR >24mo #PFS 23.2m SD = 23.7 #PFS 13.2m Path complete response 57.7% @OncoAlert🚨 @Erman_Akkus @bavilima @DrFMartinelli @lungoncdoc 🔗: ascopubs.org/doi/10.1200/JC…
Dr @cabibbo78 has a high yield #GIonc review of #IO agents in #hpbcsm #IO has transformed treatment, ⬆️ #OS and creating new #SoC. 💉 Reviews #regimens 🤝 Discusses #synergy with chemo 🚧 Highlight unmet #needs 🔗: cancertreatmentreviews.com/article/S0305-… @OncoAlert🚨 @PallOncCoP
New from @Mosunm_O and @WinshipAtEmory investigators | Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #HPBCSM
#GIonc commentary on #hpbcsm in @myESMO as we roll into #GI25. Addition of #IO to standard induction #chemo 💉 (Cis+Gem) improves #OS. Maintenance 💉 offers ⬇️ benefit, #IO alone less toxic but more 💰💰 @OncoAlert🚨 #OncoAlertAF @yekeduz_emre @FadiHaddad_MD @Abdallah81MD
Getting the latest research into cancers of the pancreas, small bowel & hepatobiliary tract @ #GI26 Oral Abstract Session B chaired by Dr Neehar Parikh & Dr @MyriamChalabi following a welcome & poll warm-up from Dr David Wang. #pancsm #hpbcsm brnw.ch/21wYXKz @andrewko1214
Lenvatinib yields survival benefit in hepatocellular carcinoma following progression on immunotherapy. #hpbcsm #GI23 | @ASCO ow.ly/FzPx50MwZMP
A helpful guide published by @JAMAOnc for #hpbcsm treatment for #HCC integrating guidelines from major organizations such as @ASCO @myESMO @NCCN and others in sequencing of treatments. #GIonc @OncoAlert🚨 #OncoAlertAF jamanetwork.com/journals/jamao…
Immunotherapy response induces divergent tertiary lymphoid structures in HCC @NatImmunol doi.org/10.1038/s41590… 👉 intratumoral TLS density⬆️after ICB -> MPR & RFS ⬆️ 👉CD20+CXCL13+ LAs surrogate for TLS ? 👉involuted TLS morphology after tumor regression 🥲exciting times for
If you love @OncoAlert Newsletter, you will love the Round Up 🤠📹 🌟 Pemigatinib 🎯in Advanced #Cholangiocarcinoma #hpbcsm 🌟#HIMALAYA 🏔️ tremelimumab+ durvalumab in #HCC Read more here 🔗: OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……… #OncoAlertAF @yekeduz_emre
The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 11-17, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic
Gastrointestinal cancer: Novel ICI–TKI combination improves HCC outcomes in the phase III CARES-310 trial - nature.com/articles/s4157… #ImmunoOnc #medonc #hpbcsm
#ASCO23 👇🏾TIGIT⛔️ TIRAGOlumab Addition to the Atezo➕BEV backbone for #hepatocellular cancer (HCC). Complexity of the interconnections in the immune axis. @GABOUALFA dissecting the data & putting things into context. 💡MORPHEUS platform. #HPBCSM #ASCO23 @OncoAlert
Dr @HopSTranCao et al from @MDAndersonNews describe a scoring system (MDA CHOP) for #hpbcsm #HCC including radiographic, lab and patient characteristics with a prognostic significance comparable to CLIP, CTP, BCLC and others #GIonc @RussellGWitt doi.org/10.1093/oncolo…
Time for 1st #ASCO23 poll. 🙋🏻♂️ First➕phase-3 trial in adjuvant HCC setting: Adjuvant Atezo➕BEV 78% 🆚 65% 12 month RFS rate. For hepatocellular cancer (HCC) #HPBCSM. @OncoAlert #ASCO23 #Immunotherapy ❓Time to include in guidelines? Practice changing? @ASCO
New & available #OpenAccess | Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis acsjournals.onlinelibrary.wiley.com/doi/full/10.10… @OncoAlert #HPBCSM
🚨 Interim findings from EMERALD-3 are here 📈 Durvalumab plus tremelimumab and lenvatinib with TACE significantly improved PFS for patients with unresectable hepatocellular carcinoma eligible for embolization. hubs.li/Q049zm3S0 #hpbcsm #LiverCancer #Oncology #Cancer |
🎥Julien Edeline, MD, PhD, presents CHIEF real-world data in advanced HCC: 🔹 2L therapy less accessible post-IO 🔹 TKI outcomes similar regardless of 1L 🔹 IO rechallenge looks promising but may reflect selection bias. ➡️ ow.ly/1kYu50WU8LW @myESMO #GI25 #HPBCsm #UroOnc
vjoncology.com
Second-line treatment patterns after first-line immunotherapy in HCC
Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses real-world data from the CHIEF cohort, which assessed second-line treatment outcomes in advanced hepatocellular carcinoma...
📢Precision oncology is transforming BTC treatment: ✅ FGFR2 & IDH1 inhibitors ✅ HER2-targeted therapy ✅ ICI-based combinations as new SOC ✅ Functional precision tools for resistance 🌟Dive into the science & trials driving change: ow.ly/Vq4h50WG32N #BTC #HPBCsm
Combining oxaliplatin with raltitrexed as hepatic arterial infusion chemotherapy demonstrated antitumor activity and long-term survival benefits among patients with unresectable hepatocellular carcinoma. #hpbcsm hubs.li/Q03wLdWy0
The FDA has approved SIR-Sphere Y-90 resin microspheres as a treatment for patients with hepatocellular carcinoma. #hpbcsm | @FDAOncology hubs.li/Q03w1F7m0
Dr @cabibbo78 has a high yield #GIonc review of #IO agents in #hpbcsm #IO has transformed treatment, ⬆️ #OS and creating new #SoC. 💉 Reviews #regimens 🤝 Discusses #synergy with chemo 🚧 Highlight unmet #needs 🔗: cancertreatmentreviews.com/article/S0305-… @OncoAlert🚨 @PallOncCoP
Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer #BiliaryTractCancer #hpbcsm onclive.com/view/zanidatam…
Nivolumab plus ipilimumab significantly improved overall survival compared with lenvatinib or sorafenib in patients with previously untreated hepatocellular carcinoma. #hpbcsm #oncology hubs.li/Q03n-Dfr0
Hypofractionated radiation therapy demonstrated local portal vein tumor thrombosis control and promising overall survival outcomes in patients with hepatocellular carcinoma. #hpbcsm #RadOnc hubs.li/Q03kLj5r0
SBRT demonstrated positive 3-year outcomes as a treatment in patients with early-stage HCC based on results from the phase 2 STRSPH trial. #hpbcsm #RadOnc hubs.li/Q03k80PX0
If you love @OncoAlert Newsletter, you will love the Round Up 🤠📹 🌟 Pemigatinib 🎯in Advanced #Cholangiocarcinoma #hpbcsm 🌟#HIMALAYA 🏔️ tremelimumab+ durvalumab in #HCC Read more here 🔗: OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……… #OncoAlertAF @yekeduz_emre
The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 11-17, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic
📰Extra! Extra!📰 @OncoAlert Newsletter is live #GIonc studies include: 🌟 Pemigatinib 🎯in Advanced #Cholangiocarcinoma #hpbcsm 🌟#HIMALAYA 🏔️ tremelimumab+ durvalumab in #HCC Never miss an edition by signing up here: OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……
The OncoAlert🚨Newsletter, EVERY WEEK! This week Covering April 11-17, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing ✅TALAPRO2 in #ProstateCancer ✅SBRT☢️ & IO in #KidneyCancer ✅ Challenges in #SCLC heterogeneity &Plasticity🫁
Important ➖trial in #hpbcsm. Intrahepatic T-VEC+pembrolizumab ⬇️ efficacy in liver mets & unresectable #HCC, w/ ⬇️ response rates across tumor types. Safety findings were consistent w/ known profiles, but results do not support further evaluation #GIonc doi.org/10.1093/oncolo…
Tovecimig Plus Paclitaxel Meets ORR End Point in Second-Line Biliary Tract Cancer #hpbcsm #Oncology onclive.com/view/tovecimig…
SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors @myESMO #hpbcsm #HCC onclive.com/view/sar444200…
The @EMA_News CHMP has adopted a positive opinion regarding frontline nivolumab/ipilimumab in unresectable or advanced hepatocellular carcinoma based on findings from the phase 3 CheckMate -9DW trial #hpbcsm #oncology #MedTwitter hubs.li/Q0383W410
The @EMA_News CHMP has recommended the approval of nivolumab paired with ipilimumab for the frontline treatment of adult patients with unresectable or advanced HCC. #hpbcsm #oncology #MedTwitter hubs.li/Q0383VCc0
No survival benefit for nab-paclitaxel plus gemcitabine/cisplatin in advanced biliary tract cancer was shown, based on results from SWOG S1815. @rachnatshroff @UAZCancer #hpbcsm #oncology hubs.li/Q037Qgt-0
Nab-paclitaxel + gemcitabine/cisplatin did not produce a statistically significant difference in OS and PFS outcomes vs gemcitabine/cisplatin alone in patients with newly diagnosed advanced biliary tract cancer. @rachnatshroff @UAZCancer #hpbcsm #oncology hubs.ly/Q037sXTX0
Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC. @ASCO #GI25 #hpbcsm #oncology hubs.li/Q036rYk-0
Gastrointestinal cancer: Novel ICI–TKI combination improves HCC outcomes in the phase III CARES-310 trial - nature.com/articles/s4157… #ImmunoOnc #medonc #hpbcsm
💡Not uncommon to have a multi-disciplinary approach to something locoregional in tandem with the systemic therapy. I’ve been favoring the STRIDE regimen for that reason if that’s the case. Also, once a month DURVA alone in the long run. Likely lower costs. No VEGF⛔️. #HPBCSM
#ASCO23 👇🏾TIGIT⛔️ TIRAGOlumab Addition to the Atezo➕BEV backbone for #hepatocellular cancer (HCC). Complexity of the interconnections in the immune axis. @GABOUALFA dissecting the data & putting things into context. 💡MORPHEUS platform. #HPBCSM #ASCO23 @OncoAlert
Aptly named BEER🍻 BTC #Ph2 trial in @JCO_ASCO In advanced #hpbcsm switching maintenance between 🍺bevacizumab ↔️ 🥃erlotinib after 6 months of gemcitabine-based therapy ⬆️ #PFS over active surveillance. #GIonc @OncoAlert🚨 ascopubs.org/doi/10.1200/JC…
Updates on GI oncology including #pancsm #crcsm #hpbcsm to be presented by @JoeHermanMD at Northwell's Best of Radiation Oncology next week! Register here: ccevent.site/2023-01-13-ro/… #radonc @PanCAN #pancreaticcancer @PancreaticCanUK @AnujGoenkaMD @PottersMD
A helpful guide published by @JAMAOnc for #hpbcsm treatment for #HCC integrating guidelines from major organizations such as @ASCO @myESMO @NCCN and others in sequencing of treatments. #GIonc @OncoAlert🚨 #OncoAlertAF jamanetwork.com/journals/jamao…
Exciting data from ReFocus in small numbers for FGFR2 inhibition in Cholangiocarcinoma with RLY-4008. ORR: 73% with nearly 1 year duration of response in FGFR inhibitor-naive pts with fusions. #ASCO23 #hpbcsm #CancerResearch
In a new Comment article, Josep Llovet uses hepatocellular carcinoma as an example to explore a new pathway for biomarker-based approval of immunotherapies: nature.com/articles/s4157…. Also see: nature.com/articles/s4157… #hpbcsm #livercancer #Immunotherapy #ImmunoOnc #hpeonc
In one of the largest studies on robotic liver resection to date, research led by our Dr. Karim Halazun (@theliversurgeon) confers that robotic liver resection offers significant advantages over open surgery in hepatobiliary carcinoma. #HPBCSM Learn more: bit.ly/3Gusm0c
Tucatinib and trastuzumab in HER2+ biliary tract cancer: 🔹️46.7% ORR, 1 CR 🔹️Median DoR: 6 months 🔹️Median PFS and OS: 5.5 and 15.5 months, respectively. 🔹️Chemo-free regimen Very encouraging! #ASCO23 #hpbcsm #CancerResearch
In a new Review, Greg Gores & co. discuss advances in cholangiocarcinoma over the past 5 yrs, focusing on the immune TME, CAFs, molecular diagnostics & classifications, target therapy, immunotherapy & transplantation: nature.com/articles/s4157… #hpbcsm #medonc #camoldx #camicroenv
Continuing HER2 story in biliary tract cancers, bispecific Ab Zanidatamab (HERIZON-BTC-01): ⚡️ORR: 41.3%, 1 CR ⚡️Median DoR: 12.9 months 🔥 ⚡️Median PFS: 5.5 months, OS not mature Most common AEs: diarrhea, infusion reactions, rare cardiac events #ASCO23 #hpbcsm #CancerResearch
Oncology precision medicine for hepatobiliary and pancreatic cancer: an institutional review - @GeoffBelliniMD Godden @JimW9200 Chevinsky @WesleyPapenfuss @mtmdphd @Aurora_Cancer #ASCO19 Abstract e14626 ow.ly/J66c50DEC2f #PrecisionMedicine #hpbcsm #pancsm
IMBRAVE050 Adjuvant Atezo➕BEV For hepatocellular cancer (HCC) #HPBCSM. @OncoAlert #ASCO23 78% 🆚 65% 12 month RFS rate. What do folks think? Good enough as an endpoint or wait till OS data?
#GIonc commentary on #hpbcsm in @myESMO as we roll into #GI25. Addition of #IO to standard induction #chemo 💉 (Cis+Gem) improves #OS. Maintenance 💉 offers ⬇️ benefit, #IO alone less toxic but more 💰💰 @OncoAlert🚨 #OncoAlertAF @yekeduz_emre @FadiHaddad_MD @Abdallah81MD
#GIonc in @JAMAOnc #ACCORD trial: Adjuvant camrelizumab + chemoradiation vs observation in resected EHC/GBC (n=93) #hpbcsm ⬆️ #OS (3y 58% vs 31%) + #RFS (3y 40% vs 17%) ⬇️ #tox Synergistic over chemo alone 💉☢️ 🔗: jamanetwork.com/journals/jamao… @doctorC369 @RyanNipp @supriyadocc
1/3 Our poster at #ASCO24, presented by Debashis Sarker on the 𝟭𝘀𝘁 𝗼𝗳 𝗝𝘂𝗻𝗲 (9am session), describes developing a predictive model of response to atezolizumab and bevacizumab (AB) in advanced #HCC meetings.asco.org/2024-asco-annu… #hpbcsm
New from @Mosunm_O and @WinshipAtEmory investigators | Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #HPBCSM
👇🏾Not surprising to see that occurrence of immune related adverse events (iRAEs) has an impact on survival for patients with hepatocellular cancer (HCC) getting the new STRIDE regimen. T3️⃣0️⃣0️⃣➕D #HPBCSM #ASCO23 @OncoAlert Most iRAEs within 3-months. OS: 23m🆚14.1m
⚡️#GIonc Update⚡️IMbrave150 🦾 Atezo + bev in #HCC #hpbcsm 77.8% partial response (PR) + 41 stable disease (SD) PR >24mo #PFS 23.2m SD = 23.7 #PFS 13.2m Path complete response 57.7% @OncoAlert🚨 @Erman_Akkus @bavilima @DrFMartinelli @lungoncdoc 🔗: ascopubs.org/doi/10.1200/JC…
Something went wrong.
Something went wrong.
United States Trends
- 1. #BIEBERCHELLA N/A
- 2. Good Sunday N/A
- 3. SimpleChain Testnet N/A
- 4. #ImmortalCF N/A
- 5. Big Sean N/A
- 6. NO PRESSURE N/A
- 7. U SMILE N/A
- 8. One Less Lonely Girl N/A
- 9. #Coachella N/A
- 10. Billie N/A
- 11. Weekend 2 N/A
- 12. DataIPO N/A
- 13. BNB Chain N/A
- 14. My Way N/A
- 15. #ZNNSTILLWITHZON N/A
- 16. ILL SEE YALL SOON N/A
- 17. Sinatra N/A
- 18. ONE TIME N/A
- 19. New Glenn N/A
- 20. Bengals N/A